Drug Design, Development and Therapy
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is now a member of the Open Access Initiative
An Author's Guide
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Development of oral immunomodulatory agents in the management of multiple sclerosis
(15783) Total Article Views
Authors: Nicholas R, Giannetti P, Alsanousi A, Friede T, Muraro PA
Published Date May 2011
Volume 2011:5 Pages 255 - 274
Richard Nicholas1,2, Paolo Giannetti2, Ali Alsanousi2, Tim Friede3, Paolo A Muraro1,2
1Imperial College Healthcare NHS Trust, London, UK; 2Centre for Neurosciences, Division of Experimental Medicine, Department of Medicine, Imperial College London, UK; 3Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany
Abstract: The emergence of oral disease-modifying therapies in multiple sclerosis (MS) will have a significant impact on the evolving scenario of immunomodulatory treatments in MS where current therapies are all injectable. Reducing relapses in trials translates for individuals with MS into a therapeutic aim of stopping future events. Thus the possible absence of any perceived benefits to the individual together with the long disease course, variable outcome, and a younger age group affected in MS makes side effects the major issue. The use of disease-modifying therapies as a whole needs to be placed in the context of a widening therapeutic indication where the use of these therapies is being justified at an increasingly early stage and in pre-MS syndromes such as clinically isolated and radiologically isolated syndromes where no fixed disability is likely to have accumulated. The five oral therapies discussed (cladribine, fingolimod, laquinimod, BG-12, and teriflunomide) have just completed Phase III studies and some have just been licensed. New oral drugs for MS need to be placed within this evolving marketplace where ease of delivery together with efficacy and side effects needs to be balanced against the known issues but also the known long-term safety of standard injectables.
Keywords: multiple sclerosis, immunomodulatory treatment, cladribine, fingolimod, laquinimod, BG-12, teriflunomide
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
Readers of this article also read:
"I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University.
- Cancer Pharmacogenomics and Targeted Therapies
17 - 19 September, 2014
- ESMO 2014 Congress
26 - 30 September, 2014
- 27th ECNP Congress
18 - 21 October, 2014
- ISPOR 17th Annual European Congress 2014
8 - 12 November, 2014
Amsterdam, The Netherlands
- 26th EORTC-NCI-AACR SYMPOSIUM 2014
18 - 21 November, 2014
- Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer
- Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis
- The benefits and risks of testosterone replacement therapy: a review
- Tenofovir-associated bone density loss